Intranasal Corticosteroid Sprays: Examples and Dosing
Multiple intranasal corticosteroid formulations are available for treating allergic rhinitis and rhinosinusitis, with specific FDA-approved dosing regimens that vary by age and indication. 1
Available Intranasal Corticosteroid Preparations
Over-the-Counter Options
- Triamcinolone acetonide (Nasacort Allergy 24HR): 55 µg per spray, aqueous formulation 1
- Ages 2-5 years: 1 spray per nostril daily
- Ages 6-11 years: 2 sprays per nostril daily
- Ages ≥12 years: 2 sprays per nostril once or twice daily
- Common side effects: pharyngitis, epistaxis, cough 1
Prescription Formulations
Mometasone furoate (Nasonex): 50 µg per spray, aqueous 1
- Ages 2-11 years: 1 spray per nostril daily
- Ages ≥12 years: 2 sprays per nostril daily
- For nasal polyps (≥18 years): 2 sprays per nostril twice daily
- Common side effects: headache, viral infection, pharyngitis, epistaxis, cough 1
Fluticasone propionate (Flonase): 50 µg per spray, aqueous 1
Fluticasone furoate (Veramyst): 27.5 µg per spray, suspension 1
- Ages 2-11 years: 1-2 sprays per nostril daily
- Ages >11 years: 2 sprays per nostril daily
- Common side effects: epistaxis, headache, pharyngolaryngeal pain 1
Budesonide (Rhinocort AQ): 32 µg per spray, aqueous 1
Ciclesonide (Omnaris): 50 µg per spray, aqueous suspension 1
- Ages ≥6 years: 2 sprays per nostril daily
- Common side effects: epistaxis, headache, nasopharyngitis 1
Ciclesonide (Zetonna): 37 µg per spray, HFA-propelled aerosol 1
- Ages ≥12 years: 1 spray per nostril daily
- Common side effects: nasal discomfort, epistaxis, headache 1
Flunisolide (Nasalide or Nasarel): 25 µg per spray, 0.025% solution 1
Clinical Efficacy Considerations
Intranasal corticosteroids are the most effective monotherapy for seasonal and perennial allergic rhinitis, superior to oral antihistamines and leukotriene receptor antagonists. 1 They effectively control all four major symptoms: sneezing, itching, rhinorrhea, and nasal congestion 1
Onset of Action
- Therapeutic effect occurs within 12 hours in most patients 1
- Some patients experience relief as early as 3-4 hours 1
- For optimal delivery, consider short-term nasal decongestant use (several days) when initiating therapy if nasal airway is significantly obstructed 1
Comparative Effectiveness
- No clear evidence that one intranasal corticosteroid is more effective than another for treating allergic rhinitis 3, 4
- All formulations demonstrate similar efficacy and adverse event profiles when used at recommended doses 2, 5
- Higher doses may provide marginally better polyp reduction but increase epistaxis risk (RR 2.06,95% CI 1.20-3.54) without clear symptom benefit 3
Safety Profile
Common Adverse Effects
- Epistaxis is the most common side effect, occurring in 5-10% of patients regardless of formulation 5
Systemic Effects
- Minimal systemic corticosteroid effects at recommended doses in adults 1
- No clinically significant HPA axis suppression demonstrated in children 1
- Transient growth effects may occur in children with specific products, though this is dose-dependent 1
- Use lowest effective dose in pediatric patients 1
Important Contraindications
- History of hypersensitivity to medication or components (applies to all formulations) 1
Key Clinical Pearls
- Continuous daily use is more effective than as-needed administration for seasonal allergic rhinitis, though PRN use (55-62% of days) can provide significant relief 1
- Patient preference regarding sensory attributes (taste, smell, nasal sensation) may affect adherence—budesonide and triamcinolone are generally preferred over mometasone and fluticasone based on sensory characteristics 2
- Intranasal corticosteroids should be considered for initial treatment without requiring prior trial of antihistamines or oral decongestants 1
- Periodically examine nasal septum to ensure no mucosal erosions are developing 1